Associations with fracture in patients with diabetes: A nested case-control study

BMJ Open

Volumn 6, Issue 2, 2016, Pages

  Starup Linde, Jakob ^a,b   Gregersen, Søren ^a   Vestergaard, Peter ^b,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BIGUANIDE DERIVATIVE; BIOCHEMICAL MARKER; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; DRUG USE; FEMALE; FRACTURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; BLOOD; BONE DENSITY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRINKING BEHAVIOR; RISK FACTOR; TIME FACTOR;

AGE FACTORS; AGED; ALCOHOL DRINKING; ANTICONVULSANTS; BONE DENSITY; CASE-CONTROL STUDIES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS;

EID: 84960424845     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009686     Document Type: Article

References (40)

1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007;18:427-44.
2. Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495-505.
3. Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012;27:301-8.
4. Mayne D, Stout NR, Aspray TJ. Diabetes, falls and fractures. Age Ageing 2010;39:522-5.
5. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006;91:3404-10.
6. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001;86:32-8.
7. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009;84:45-55.
8. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005;48:1292-9.
9. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab 2010;28:554-60.
10. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51.
11. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 2008;31:199-203.
12. Bazelier MT, De Vries F, Vestergaard P, et al. Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol (Lausanne) 2013;4:11.
13. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-9.
14. Li CI, Liu CS, Lin WY, et al. Glycated hemoglobin level and risk of hip fracture in older people with type 2 diabetes: a competing risk analysis of Taiwan Diabetes Cohort Study. J Bone Miner Res 2015;30:1338-46.
15. Neumann T, Lodes S, Kästner B, et al. High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control. Osteoporos Int 2014;25:1527-33.
16. Ahmed LA, Schirmer H, Berntsen GK, et al. Features of the metabolic syndrome and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int 2006;17:426-32.
17. Trimpou P, Odén A, Simonsson T, et al. High serum total cholesterol is a long-term cause of osteoporotic fracture. Osteoporos Int 2011;22:1615-20.
18. Dennison EM, Compston JE, Flahive J, et al. Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 2012;50:1288-93.
19. Von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Int J Surg 2014;12:1495-9.
20. Sniderman AD, Blank D, Zakarian R, et al. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem 2003;36:499-504.
21. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from The National Osteoporosis Risk Assessment. JAMA 2001;286:2815-22.
22. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31(Suppl 1):S12-54.
23. Rutter MK, Nesto RW. Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. Eur Heart J 2011;32:2247-55.
24. Kruse C, Eiken P, Vestergaard P. Continuous and long-term treatment is more important than dosage for the protective effect of thiazide use on bone metabolism and fracture risk. J Intern Med 2016;279:110-22.
25. Xiao F, Qu X, Zhai Z, et al. Association between loop diuretic use and fracture risk. Osteoporos Int 2015;26:775-84.
26. Napoli N, Strotmeyer ES, Ensrud KE, et al. Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 2014;57:2057-65.
27. Nakchbandi IA. Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications. World J Gastroenterol 2014;20:9427-38.
28. Ghadir MR, Riahin AA, Havaspour A, et al. The relationship between lipid profile and severity of liver damage in cirrhotic patients. Hepat Mon 2010;10:285-8.
29. Tolman KG, Fonseca V, Dalpiaz A, et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30:734-43.
30. Sato T, Morita I, Murota S. Involvement of cholesterol in osteoclastlike cell formation via cellular fusion. Bone 1998;23:135-40.
31. Luegmayr E, Glantschnig H, Wesolowski GA, et al. Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ 2004;11(Suppl 1):S108-18.
32. Goettsch C, Rauner M, Sinningen K, et al. The osteoclast-associated receptor (OSCAR) is a novel receptor regulated by oxidized low-density lipoprotein in human endothelial cells. Endocrinology 2011;152:4915-26.
33. Dong Y, Lathrop W, Weaver D, et al. Molecular cloning and characterization of LR3, a novel LDL receptor family protein with mitogenic activity. Biochem Biophys Res Commun 1998;251:784-90.
34. Klein BY, Rojansky N, Ben-Yehuda A, et al. Cell death in cultured human Saos2 osteoblasts exposed to low-density lipoprotein. J Cell Biochem 2003;90:42-58.
35. Zhang J, Zhang X, Zhang L, et al. LRP8 mediates Wnt/beta-catenin signaling and controls osteoblast differentiation. J Bone Miner Res 2012;27:2065-74.
36. Beisiegel U, Weber W, Ihrke G, et al. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989;341:162-4.
37. Saarinen A, Saukkonen T, Kivelä T, et al. Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia. Clin Endocrinol (Oxf) 2010;72:481-8.
38. Peña JM, Aspberg S, MacFadyen J, et al. Statin Therapy and Risk of Fracture: Results From the JUPITER Randomized Clinical Trial. JAMA Intern Med 2014;175:171-7.
39. Bauer DC. HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 2003;14:273-82.
40. Shamai L, Lurix E, Shen M, et al. Association of body mass index and lipid profiles: evaluation of a broad spectrum of body mass index patients including the morbidly obese. Obes Surg 2011;21:42-7.